BlackRock Health Sciences Term Trust (BMEZ) offered to repurchase for cash up to 5% of its issued and outstanding common shares of beneficial interest. The purchase price is 98% of net asset value (NAV) per share, with NAV determined at the close of regular trading on the NYSE on the next day NAV is calculated after the offer expires. The Trust had 62,501,404 shares issued and outstanding as of October 9, 2026.
BlackRock Health Sciences Term Trust (BMEZ) has a Board-authorized tender offer for up to 5% of its outstanding common shares. Its average daily discount to NAV was 11.05% for the Measurement Period ended September 30, 2026, exceeding the program’s greater-than-10.00% trigger. The anticipated commencement date is October 16, 2026; the offer is scheduled to expire November 18, 2026, at 5:00 p.m. Eastern Time, unless extended.
The offer price is 98% of NAV per share, based on NAV calculated on the next day it is calculated after expiration (or after an extended expiration, if applicable). If more than 5% of shares are tendered, purchases will be made pro rata, and the Fund says there is no assurance it will purchase all shares a shareholder tenders. Payments for accepted shares are expected within approximately five business days after expiration.
BlackRock Health Sciences Term Trust (BMEZ) filed an initial ownership report indicating that Francis C. Mahoney is a director of the trust. The filing reports no securities transactions or holdings for Mahoney at this time.
BlackRock Health Sciences Term Trust reports that Charles Park is serving as its Chief Compliance Officer. Park previously held this role from January 28, 2020 to June 30, 2023 and has been reappointed effective August 1, 2026. No securities holdings or transactions are reported in this insider statement.
BMEZ submitted an annual Form N-CEN reporting fund operations and service relationships for the covered period. The filing lists securities lending activity with a monthly average value of 7,903,999.64 and net securities lending income of 79,658.
The report also discloses aggregate brokerage commissions of 1,268,977.69 and principal trading relationships including a counterparty trade value of 1,964,400,832.54, with multiple broker and dealer records itemized in the tables.
BlackRock Health Sciences Term Trust (BMEZ) filed its certified shareholder report for the fiscal period ended 12/31/2025, reporting portfolio results and supplemental disclosures. The Trust states a monthly distribution of $0.110000 per share (annualized $10) and shows total cumulative distributions of $1.871060 per common share for the fiscal period, composed of 25% long-term net realized gains and 75% return of capital.
The report discloses that the Trust changed its investment objectives and removed its options writing/overwrite strategy effective 11/10/2025. As of period end the portfolio mix lists biotechnology, medical devices & supplies, and pharmaceuticals as the largest industry weightings with top holdings and industry allocations provided in the Schedule of Investments.
Liu Xiang, a portfolio manager for BlackRock Health Sciences Term Trust, reported multiple equity-related transactions dated January 30, 2026. The filing shows the exercise of derivative awards into 777.9221 shares of common stock, followed by a same-day sale of those 777.9221 shares at $15.21 per share, leaving no directly held common stock.
The transactions also include an award of 1,026.693 phantom shares at a reference value of $15.21. Each phantom share is the economic equivalent of one share of common stock and is payable in cash, vesting in equal installments on each of the first three anniversaries of the award.
BlackRock Health Sciences Term Trust (BMEZ) portfolio manager Erin H. Xie reported a mix of phantom share awards, exercises, and a stock sale on January 30, 2026. Xie was granted 17,560.4931 phantom shares, each economically equivalent to one common share and payable in cash subject to vesting.
On the same date, Xie exercised previously granted phantom shares into 25,676.2744 common shares, then disposed of all 25,676.2744 common shares in a sale at $15.21 per share, leaving no directly owned common stock after the transactions. The phantom share awards vest in equal installments over three years.
BlackRock Health Sciences Term Trust director reports share sales in Form 4 filing. The director sold 10,294 common shares of BMEZ on 12/18/2025 at a price of $14.98 per share, followed by a sale of 0.422 share on 12/19/2025 at $14.96 per share. After these direct transactions, the director no longer held the shares directly. The filing also reports corresponding transactions in common stock held indirectly by the director's spouse on the same dates and prices, with those indirect holdings also reduced to zero. The report is filed for one reporting person, who serves as a director of the trust, and is signed by an attorney-in-fact.